Iowa-based Integrated DNA Technologies, a genomics solutions provider, has acquired Ann Arbor’s Swift Biosciences, which develops sequencing preparation kits for genomics.
An organism’s genome is its genetic material, and DNA sequencing allows researchers to determine the makeup of genetic material. Terms of the deal were not disclosed.
“We have been impressed with the Swift products and organizational talent,” says Trey Martin, president of Integrated DNA. “Swift’s research tools are being used for cancer, inherited disease, and other health applications, as well as research in agrigenomics, metagenomics, and the biotech/pharmaceutical industry.”
Swift offers its sequencing products for academic, translational, and clinical research. Integrated DNA develops and manufactures products for academic and commercial research, agriculture, medical diagnostics, pharmaceutical development, and synthetic biology.
“The synergies between IDT and Swift make this acquisition an excellent fit,” says Nathan Wood, president and CEO of Swift. “Since entering the NGS market in 2013, Swift’s mission has been to provide research tools for long term improvements in the health of individuals and their communities all around the world. IDT has the commercial engine, operational tools, and resources to catalyze these efforts.”
Swift associates and products will transition into Integrated DNA and will continue to operate from its Ann Arbor facility.
Integrated DNA has manufacturing sites in San Diego, North Carolina, Belgium, and Singapore.